Trial · NCT07907692
Impact of High Thoracic Paravertebral Block on Diaphragmatic Function: a Prospective Study
NCT07907692, Not applicable, Not yet recruiting, Ciusss de L'Est de l'Île de Montréal
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Impact of High Thoracic Paravertebral Block on Diaphragmatic Function: a Prospective Study. Trials, record NCT07907692. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07907692
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Impact of High Thoracic Paravertebral Block on Diaphragmatic Function: a Prospective Study
- NCT number
- NCT07907692
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 40 participants, estimated
- Lead sponsor
- Ciusss de L'Est de l'Île de Montréal
- Conditions
- Breast Cancer Surgery, Breast Cancer Surgery Pain, Hemidiaphragmatic Paralysis
- Interventions
- High thoracic paravertebral block
- First posted
- 2026-10-30
- Last updated
- 2026-10-30
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of ipsilateral hemidiaphragmatic dysfunction determined by diaphragm ultrasonography | Postoperative assessment in the PACU, approximately 1-3 hours after block placement. | The incidence of ipsilateral hemidiaphragmatic paralysis following high thoracic paravertebral block, assessed by diaphragm ultrasonography using the diaphragmatic thickening fraction (DTF). |
| Secondary | Change in ipsilateral diaphragmatic excursion | Baseline (before block) and postoperative assessment in the PACU, approximately 1-3 hours after block placement. | Change in ipsilateral diaphragmatic excursion from baseline (pre-block) to postoperative assessment measured by diaphragm ultrasonography. |
| Secondary | Postoperative dyspnea | From PACU admission to PACU discharge (approximately 1-3 hours). | Incidence and intensity of dyspnea assessed in the PACU using a numerical rating scale (NRS 0-10). |
| Secondary | Oxygen desaturation | From PACU admission to PACU discharge (approximately 1-3 hours). | Incidence of oxygen desaturation episodes, defined as oxygen saturation below 92%. |
| Secondary | Supplemental oxygen requirement | From PACU admission to PACU discharge (approximately 1-3 hours). | Requirement for supplemental oxygen during PACU stay. |
| Secondary | Postoperative pain intensity | From PACU admission to PACU discharge (approximately 1-3 hours). | Pain intensity assessed in the PACU using a numerical rating scale (NRS 0-10). |
| Secondary | Postoperative opioid consumption | From PACU admission to PACU discharge (approximately 1-3 hours). | Total postoperative opioid consumption in the PACU, expressed as morphine milligram equivalents (MME). |
| Secondary | Inadvertent brachial plexus block | After block placement until discharge from the PACU (approximately 1-3 hours). | Incidence of inadvertent brachial plexus block following high thoracic paravertebral block. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07907692
GET https://conductscience.org/api/trials/v1/NCT07907692/registered